Logo

Gene Logic Says Genomics Revenue Significantly Lower Than Expected for Q2 and 2005

Jun 22, 2006

NEW YORK, June 22 (GenomeWeb News) - Gene Logic said today that revenue for its genomics division will be "significantly lower" than anticipated for both the second quarter and the full year of 2006, and it is withdrawing its financial guidance for 2006 and 2007 as a result.

 

The disappointing revenues will adversely impact operating results for the genomics division "for the foreseeable future," the company said.

 

The company said it is performing a review of the genomics division's strategy, and it expects to announce those results within 90 days. The performance of Gene Logic's drug-repositioning division and its preclinical division will not deviate significantly from estimates, the company said.

 

The company's senior vice president and general manager of genomics has resigned for "personal reasons and to pursue other career opportunities," the company said.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.